Tevogen advances talks on strategic acquisitions, including CRO deal under review

Tevogen Bio Holdings Inc.

Tevogen Bio Holdings Inc.

TVGN

0.00
  • Tevogen Bio Holdings is pursuing strategic acquisitions, including evaluation of a contract research organization, targeting about $100 million in combined annual revenue.
  • The deals are intended to add a healthcare services arm alongside Tevogen Bio and Tevogen.AI as the group pushes toward financial self-sufficiency.
  • Any transactions remain subject to due diligence, definitive agreements, required approvals, and customary closing conditions.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tevogen Bio Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605281230PRIMZONEFULLFEED9728330) on May 28, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.